<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03779178</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0743</org_study_id>
    <secondary_id>2018-000307-17</secondary_id>
    <nct_id>NCT03779178</nct_id>
  </id_info>
  <brief_title>Landiolol in Postoperative Atrial Fibrillation</brief_title>
  <acronym>MMELPOAF</acronym>
  <official_title>Microcirculatory and Macrocirculatory Effects of Landiolol in Prevention of Postoperative Atrial Fibrillation: a Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative atrial fibrillation is a common complication after cardiac surgery and is
      associated with an elevation of morbidity and mortality. The recommended treatment includes
      heart rate control with a beta blocker. Landiolol is a new-generation beta-blocker with
      favourable pharmacologic properties making an interesting drug to treat postoperative atrial
      fibrillation. However, Landiolol micro and macrocirculatory effects in the setting of atrial
      fibrillation are yet to describe. The aim of this study is to describe microcirculatory
      effects of incremental doses of landiolol in postoperative atrial fibrillation compared to a
      placebo. Our hypothesis is Landiolol will improve microcirculation disorders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Actual">December 4, 2019</completion_date>
  <primary_completion_date type="Actual">December 4, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissular resaturation speed measured by somatic near-infrared spectroscopy (NIRS)</measure>
    <time_frame>at 20 minutes</time_frame>
    <description>Tissular resaturation speed is measured after vascular occlusion test. At each time end-point, an occlusion of the arm blood flow with a tourniquet is made. After the nadir of the tissular saturation of the arm is reached the tourniquet is released and the resaturation speed is measured using the NIRS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissular resaturation speed measured by somatic near-infrared spectroscopy (NIRS)</measure>
    <time_frame>at 40 minutes</time_frame>
    <description>Tissular resaturation speed is measured after vascular occlusion test. At each time end-point, an occlusion of the arm blood flow with a tourniquet is made. After the nadir of the tissular saturation of the arm is reached the tourniquet is released and the resaturation speed is measured using the NIRS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissular resaturation speed measured by somatic near-infrared spectroscopy (NIRS)</measure>
    <time_frame>at 60 minutes</time_frame>
    <description>Tissular resaturation speed is measured after vascular occlusion test. At each time end-point, an occlusion of the arm blood flow with a tourniquet is made. After the nadir of the tissular saturation of the arm is reached the tourniquet is released and the resaturation speed is measured using the NIRS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissular resaturation speed measured by somatic near-infrared spectroscopy (NIRS)</measure>
    <time_frame>at 80 minutes</time_frame>
    <description>Tissular resaturation speed is measured after vascular occlusion test. At each time end-point, an occlusion of the arm blood flow with a tourniquet is made. After the nadir of the tissular saturation of the arm is reached the tourniquet is released and the resaturation speed is measured using the NIRS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissular resaturation speed measured by somatic near-infrared spectroscopy (NIRS)</measure>
    <time_frame>at 100 minutes</time_frame>
    <description>Tissular resaturation speed is measured after vascular occlusion test. At each time end-point, an occlusion of the arm blood flow with a tourniquet is made. After the nadir of the tissular saturation of the arm is reached the tourniquet is released and the resaturation speed is measured using the NIRS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissular resaturation speed measured by somatic near-infrared spectroscopy (NIRS)</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>Tissular resaturation speed is measured after vascular occlusion test. At each time end-point, an occlusion of the arm blood flow with a tourniquet is made. After the nadir of the tissular saturation of the arm is reached the tourniquet is released and the resaturation speed is measured using the NIRS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microcirculatory mean flow index (MIF) acquired by sublingual microscopy</measure>
    <time_frame>at 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of perfused vessels acquired by sublingual microscopy</measure>
    <time_frame>at 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional capillary density acquired by sublingual microscopy</measure>
    <time_frame>at 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>De Backer score acquired by sublingual microscopy</measure>
    <time_frame>at 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heterogeneity of the mean flow index acquired by sublingual microscopy</measure>
    <time_frame>at 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic arterial pressure</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic arterial pressure</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac output measured by transthoracic echocardiography</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic vascular resistance</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial elastance.</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction of the left ventricle (FEVG)</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>telesystolic volumes of the right ventricle</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>telesystolic volumes of the left ventricle</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>telediastolic volumes of the right ventricle</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>telediastolic volumes of the left ventricle</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>right ventricle contractility (measured with TAPSE and tricuspid S-wave)</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intracardiac filling pressure profiles (E/a, E/Vp, E/e')</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen consumption (V02)</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>tissular perfusion parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen delivery (DO2),</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>tissular perfusion parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carbon dioxide production (VCO2)</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>tissular perfusion parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial lactate</measure>
    <time_frame>at 120 minutes</time_frame>
    <description>tissular perfusion parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Landiolol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Landiolol perfusion in incremental doses (range 0.5 to 10 µg/kg/min) over 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo perfusion in incremental doses (range 0.03 to 0.6 mL/kg/h) over 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Landiolol</intervention_name>
    <description>Landiolol perfusion over 120 minutes in incremental doses : 0.5, 1, 2, 5 and 10 µg/kg/min. Doses are modified every 20 minutes</description>
    <arm_group_label>Landiolol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo perfusion is sodium chloride NaCl 0.9% over 120 minutes in incremental doses : 0.03, 0.06, 0.12, 0.3 and 0.6 mL/kg/h. Doses are modified every 20 minutes. Perfusion are similar in landiolol group to preserve blind.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient underwent conventional cardiac surgery

          -  Age &gt; 18 years

          -  Writing contentment

        Exclusion Criteria:

          -  Pre-existing chronic atrial fibrillation

          -  Contraindication to beta-blockers

          -  Circulatory shock (cardiac index&lt;2.2 L/min and lactate&gt;4mmol/L)

          -  Distributive shock (cardiac index&gt;2.2 L/min with norepinephrine dose &gt; 0.3 µg/kg/min
             to reach mean arterial pressure &gt; 65mmHg).

          -  Acute respiratory distress

          -  Major bleeding (&gt;200mL/h)

          -  Patient already included into an interventional clinical study

          -  Pregnancy

          -  No social security insurance

          -  Patient not able to give consent (curators, patients deprived of public rights)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Jacquet-Lagrèze</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>landiolol</keyword>
  <keyword>microcirculation</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Landiolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

